Latest filing published 22 May 2008 for Fibrocell Science, Inc., €3,687.
No signal scores available.
Not enough history yet: 0 closed purchases, at least 2 are needed.
Filings by Declan Daly span 2 companies, the busiest being Fibrocell Science, Inc. and Inamed Corp. Over a trading history stretching from 17 March 2006 to 21 May 2008, the count stands at 11 filings.
Every open-market trade on record is a purchase: 9 purchases worth €39k, and no sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2008, the count stands at 5 purchases and no sales.
A typical purchase (the median) is worth €2,987.
On 22 May 2008 came the latest disclosure, an open-market purchase for €3,687 in Fibrocell Science, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations